secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001628280-23-027933
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics appoints Alfonso Quintás-Cardama as CMO; Sam Agresta departs Sept 11, 2023
--------------------------------------------------------------------------------

- Samuel Agresta steps down as CMO effective September 11, 2023; will consult through early January 2024.
- Alfonso Quintás-Cardama appointed CMO effective September 11, 2023; previously CMO at TCR2 Therapeutics.
- Dr. Quintás-Cardama helped develop Kymriah (tisagenlecleucel) at Novartis and led cell therapy clinical dev at GSK.
- He was a faculty member at MD Anderson Cancer Center (2009-2014) developing targeted agents for myeloid malignancies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023027933/0001628280-23-027933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023027933/fhtx-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer